Updates are available Correction dated 2022-12-21
Click to view Correction: https://doi.org/10.1186/s12974-022-02644-2
-
Authors
Du, Ying
Zhao, Chao
Liu, Juntong
Li, Chuan
Yan, Qi
Li, Lin
Hao, Yunfeng
Yao, Dan
Si, Huaxing
Zhao, Yingjun
Zhang, Wei
-
Funding
Funding for this research was provided by:
Ying Du (National Natural Science Foundation of China (82171406))
Chuan Li (Tangdu hospital innovation development foundation (2018QYTS010))
Wei Zhang (National Natural Science Foundation of China (81971003）)
- License Information
-
More Information
Article History
Received: 5 July 2022
Accepted: 13 October 2022
First Online: 22 October 2022
Change Date: 21 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12974-022-02644-2
Declarations
:
: We provided patients detailed information about the disease, and obtained the consent of the patients to repeated low-dose rituximab treatment. We have also reported to the Ethical Committee of Tangdu Hospital, Fourth Military Medical University, and obtained the approval from the committee.
: We obtained written informed consent from both patients for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
: The authors declare that they have no competing interest.
